Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 8.83%.

  • Cytek Biosciences' EBITDA Margin fell 112300.0% to 8.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.15%, marking a year-over-year decrease of 19300.0%. This contributed to the annual value of 2.36% for FY2024, which is 42300.0% up from last year.
  • Cytek Biosciences' EBITDA Margin amounted to 8.83% in Q3 2025, which was down 112300.0% from 10.99% recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' EBITDA Margin registered a high of 16.63% during Q4 2024, and its lowest value of 29.01% during Q1 2025.
  • For the 5-year period, Cytek Biosciences' EBITDA Margin averaged around 3.65%, with its median value being 2.22% (2022).
  • Per our database at Business Quant, Cytek Biosciences' EBITDA Margin plummeted by -326200bps in 2021 and then surged by 154800bps in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' EBITDA Margin stood at 3.39% in 2021, then surged by 117bps to 7.35% in 2022, then skyrocketed by 36bps to 9.97% in 2023, then surged by 67bps to 16.63% in 2024, then tumbled by -153bps to 8.83% in 2025.
  • Its last three reported values are 8.83% in Q3 2025, 10.99% for Q2 2025, and 29.01% during Q1 2025.